LONDON, October 3, 2017 /PRNewswire/ --
Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies
The Alzheimer's Disease Therapeutics and Diagnostics Market reached $6.71bn in 2016. The Alzheimer's Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 15.3% in the second half of the forecast period.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 207-page report you will receive 73 tables and 76 figures- all unavailable elsewhere.
The 207-page report provides clear detailed insight into the Alzheimer's Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
• Alzheimer's Disease Market forecasts from 2017-2027, further broken down into:
- Alzheimer's Drugs Market
- Alzheimer's Diagnostics Market
• Quantitative analysis of the Alzheimer's drug market from 2017 to 2027. It includes analysis and forecast of top drugs and pipeline drugs in the market:
• Quantitative analysis of the Alzheimer's diagnostics market from 2017 to 2027. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer's diagnosis from 2017to 2027:
- Diagnostic biomarker market
• Profiles of leading pharma companies involved in developing Alzheimer's drugs globally. It contains overviews of the companies' segments, recent mergers and acquisitions and analysis of the companies' recent financial performances. It also includes the details of the drugs for Alzheimer's in the pipeline and forecast of the company drugs available in the market:
- Daiichi Sankyo
- vTv Therapeutics
• Profiles of leading companies developing diagnostics tests for Alzheimer's disease:
- Eli Lilly
- Amarantus Biosciences Holdings
- Piramal Enterprises
- GE Healthcare
• This report also breaks down the revenue forecast for the Alzheimer's Disease Market by national market:
• This report covers the qualitative analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.
• This report shows transcripts of research interviews conducted by Visiongain:
- David Hung, Chief Executive Officer of Axovant Sciences Inc.
- Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
- Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.
Buy our report today Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies.
To request a report overview of this report please email Sara Peerun at firstname.lastname@example.org or call Tel: +44-(0)-20-7336-6100
List of Companies and Organizations Mentioned in the Report
Axovant Sciences Inc
AZ Therapies Inc
Bayer Schering Pharma
Bristol Myers Suibb
European Medicines Agency (EMA)
Foundation Medical Partners
Food and Drug Administration (FDA)
Janssen Alzheimer Immunotherapy Research & Development
Janssen Pharmaceutical K. K
Merck & Co
Meso Scale Diagnostics
Metabolic Solutions Development Company
National Institute of Health (NIH)
National Institute for Health and Care Excellence (NICE)
Ortho Clinical Diagnostics
Siemens Medical Solutions USA
To see a report overview please email Sara Peerun on email@example.com
SOURCE Visiongain Ltd